Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Gains from Investment Securities (2016 - 2025)

Avalo Therapeutics (AVTX) has disclosed Gains from Investment Securities for 10 consecutive years, with $1000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gains from Investment Securities rose 100.0% year-over-year to $1000.0, compared with a TTM value of -$262.2 million through Sep 2025, down 281.1%, and an annual FY2024 reading of -$121.6 million, changed N/A over the prior year.
  • Gains from Investment Securities was $1000.0 for Q3 2025 at Avalo Therapeutics, up from -$114.1 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.0 billion in Q4 2022 and bottomed at -$114.1 million in Q4 2024.
  • Average Gains from Investment Securities over 4 years is $227.3 million, with a median of -$313000.0 recorded in 2021.
  • The sharpest move saw Gains from Investment Securities plummeted 567.02% in 2021, then surged 319079.27% in 2022.
  • Year by year, Gains from Investment Securities stood at -$627000.0 in 2021, then soared by 319079.27% to $2.0 billion in 2022, then crashed by 105.71% to -$114.1 million in 2024, then skyrocketed by 100.0% to $1000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for AVTX at $1000.0 in Q3 2025, -$114.1 million in Q4 2024, and -$36.0 million in Q3 2024.